Related Experiment Video
Updated: May 8, 2026
11:34
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Cardiovascular RNA interference therapy: the broadening tool and target spectrum
Wolfgang Poller1, Juliane Tank, Carsten Skurk
1Department of Cardiology and Pneumology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany. wolfgang.poller@charite.de
Circulation Research
|August 17, 2013
Summary
Noncoding RNAs (ncRNAs) are crucial in disease pathogenesis and offer new therapeutic potential. RNA interference (RNAi) using ncRNAs provides versatile gene silencing for treating various diseases, including cardiovascular conditions.
Area of Science:
- Genomics
- Molecular Biology
- Medical Science
Background:
- The role of noncoding RNAs (ncRNAs) in complex organisms is increasingly recognized, necessitating their inclusion in disease pathogenesis studies.
- ncRNA variants are linked to significant human diseases, highlighting the inadequacy of focusing solely on protein-coding regions.
- Understanding ncRNAs is vital for developing new diagnostic and therapeutic strategies in medicine.
Purpose of the Study:
- To explore the evolutionary and discovery history of ncRNAs relevant to therapeutic potential.
- To discuss novel therapeutic strategies based on ncRNAs, particularly RNA interference (RNAi) for gene silencing.
- To review therapeutic options for cardiovascular medicine and challenges in clinical translation of ncRNA-based therapies.
Main Methods:
- Review of evolutionary and discovery history of ncRNAs.
- Discussion of RNA interference as a gene-silencing tool.
- Analysis of therapeutic applications and safety considerations of RNA therapeutics.
Main Results:
- ncRNAs are implicated in disease pathogenesis, offering therapeutic targets beyond protein-coding genes.
- RNA interference (RNAi) is a versatile tool for gene silencing, applicable to a broad spectrum of therapeutic targets.
- Technical advancements facilitate the clinical translation of ncRNA-based therapeutics, with ongoing safety evaluations.
Conclusions:
- ncRNAs represent a significant frontier in understanding disease and developing novel therapeutics.
- RNA interference offers a promising platform for gene silencing therapies, with potential applications in cardiovascular medicine.
- Despite fragmentary understanding of the noncoding genome, clinical translation of ncRNA therapeutics is feasible under specific conditions.
Related Concept Videos
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:23RNA Editing
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...